Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Current treatment options in oncology - 1 Aug 2016

Chen Ricky, Cohen Adam L, Colman Howard

Abstract excerpt

OPINION STATEMENT: High-grade gliomas remain incurable despite current therapies, which are plagued by high morbidity and mortality. Molecular categorization of glioma subtypes using mutations in isocitrate dehydrogenase 1/2 (IDH1/2), TP53, and ATRX; codeletion of chromosomes 1p and 19q; DNA methylation; and amplification of genes such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Cell Transformation, Neoplastic

Share to Epigenesis, Genetic

Share to Glioma

Share to Molecular Targeted Therapy

Share to Neoplasm Grading

Source

Identifiers

PMID: 27334978
DOI: 10.1007/s11864-016-0418-0

Genes

EGFR
IDH1
ATRX
IDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.PMID 27334978Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

Molecular biology of high-grade gliomas: what should the clinician know?Semantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensusSemantic proximity Read ↗

[Basic principles of diagnosis and treatment of gliomas].Semantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

Glioma targeted therapy: insight into future of molecular approaches.Semantic proximity Read ↗

The Evolving Molecular Landscape of High-Grade Gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.